Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Open access

Abstract

This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first mineralocorticoid to trials of nonsteroidal MRAs. The MR is a nuclear receptor expressed in many tissues/cell types including the kidney, heart, immune cells, and fibroblasts. The MR directly affects target gene expression—primarily fluid, electrolyte and haemodynamic homeostasis, and also, but less appreciated, tissue remodelling. Pathophysiological overactivation of the MR leads to inflammation and fibrosis in cardiorenal disease. We discuss the mechanisms of action of nonsteroidal MRAs and how they differ from steroidal MRAs. Nonsteroidal MRAs have demonstrated important differences in their distribution, binding mode to the MR and subsequent gene expression. For example, the novel nonsteroidal MRA finerenone has a balanced distribution between the heart and kidney compared with spironolactone, which is preferentially concentrated in the kidneys. Compared with eplerenone, equinatriuretic doses of finerenone show more potent anti-inflammatory and anti-fibrotic effects on the kidney in rodent models. Overall, nonsteroidal MRAs appear to demonstrate a better benefit–risk ratio than steroidal MRAs, where risk is measured as the propensity for hyperkalaemia. Among patients with Type 2 diabetes, several Phase II studies of finerenone show promising results, supporting benefits on the heart and kidneys. Furthermore, finerenone significantly reduced the combined primary endpoint (chronic kidney disease progression, kidney failure, or kidney death) vs. placebo when added to the standard of care in a large Phase III trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa736

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Key studies in the history of mineralocorticoid receptor antagonists.
Figure 1 Key studies in the history of mineralocorticoid receptor antagonists.CC BY-NC · PubMed Central
Figure 2 Finerenone reduces cofactor recruitment to the mineralocorticoid receptor, thereby reducing downstream expression of pro-inflammatory and pro-fibrotic factors following mineralocorticoid receptor overactivation. MR, mineralocorticoid receptor.
Figure 2 Finerenone reduces cofactor recruitment to the mineralocorticoid receptor, thereby reducing downstream expression of pro-inflammatory and pro-fibrotic factors following mineralocorticoid receptor overactivation. MR, mineralocorticoid receptor.CC BY-NC · PubMed Central
Figure 3 Mean relative exposure of spironolactone and spironolactone metabolites in healthy volunteers (n = 12). AUC, area under the concentration–time curve.
Figure 3 Mean relative exposure of spironolactone and spironolactone metabolites in healthy volunteers (n = 12). AUC, area under the concentration–time curve.CC BY-NC · PubMed Central
Figure 4 Key results of the ARTS, ARTS-HF, and ARTS-DN Phase II studies. *Significant (P ≤ 0.001); #Nominal statistical significance in the finerenone 10–20 mg group (hazard ratio = 0.56, 95% confidence interval 0.35; 0.90, P = 0.02). CV, cardiovascular; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; T2D, Type 2 diabetes; UACR, urine albumin-to-creatinine ratio.
Figure 4 Key results of the ARTS, ARTS-HF, and ARTS-DN Phase II studies. *Significant (P ≤ 0.001); #Nominal statistical significance in the finerenone 10–20 mg group (hazard ratio = 0.56, 95% confidence interval 0.35; 0.90, P = 0.02). CV, cardiovascular; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; T2D, Type 2 diabetes; UACR, urine albumin-to-creatinine ratio.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Research works printed but not linked: 1

  1. Platt, 1972, Studies on organ- and subcellular distribution of 3H-spironolactone in animals, Arzneimittelforschung, 22, 1801

Cited by

See all 638

Metadata

Authors
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F.
Affiliations
  • Indiana University School of Medicine (US)
  • Bayer (Germany) (DE)
  • University of Chicago (US)
  • Medizinische Hochschule Hannover (DE)
  • Kanazawa University (JP)
  • French Clinical Research Infrastructure Network (FR)
Corresponding author
Agarwal, Rajiv
Venue
European Heart Journal
Published
2020-10-25
Volume
42
Issue
2
Pages
152-161
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3093851112
Cited by
638
References
89
Citations by year
2026: 140 · 2025: 129 · 2024: 114 · 2023: 103 · 2022: 97 · 2021: 50 · 2020: 5
FWCI
9.87
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone, cardiorenal disease, renal fibrosis, inflammation, tissue remodeling, hyperkalemia, type 2 diabetes, chronic kidney disease progression, drug development history
MeSH terms
Mineralocorticoid Receptor Antagonists, Diabetes Mellitus, Type 2, Heart Failure, Humans, Mineralocorticoids, Spironolactone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa736
The paper
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021). Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa736

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.